On April 12, 2022 Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer, reported that management plans to participate in seven upcoming investor conferences (Press release, Allogene, APR 12, 2022, View Source [SID1234616271]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Canaccord Genuity Horizons in Oncology Virtual Conference
Thursday, April 14, 2022
8:00AM PT/11:00AM ET

BofA Securities 2022 Healthcare Conference
Tuesday, May 10, 2022
8:00AM PT/11:00AM ET

2022 RBC Capital Markets Global Healthcare Conference
Tuesday, May 17, 2022
5:30AM PT/8:30AM ET

Jefferies Global Healthcare Conference
Wednesday, June 8-Thursday, June 9, 2022
Details to be posted to the Company’s website

Goldman Sachs 43rd Annual Global Healthcare Conference
Monday, June 13, 2022
Details to be posted to the Company’s website

2022 Truist Securities Cell Therapy Symposium
Tuesday, June 28, 2022
Details to be posted to the Company’s website

Stifel Virtual Cell Therapy Conference
Thursday, June 30, 2022
8:30AM PT/11:30AM ET

Any available webcasts will be posted to the Company’s website at www.allogene.com under the Investors tab in the News and Events section. Following the live webcast, a replay will be available on the Company’s website for approximately 30 days.